[go: up one dir, main page]

MX2018004366A - Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos. - Google Patents

Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.

Info

Publication number
MX2018004366A
MX2018004366A MX2018004366A MX2018004366A MX2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A
Authority
MX
Mexico
Prior art keywords
cells
epic
sorting
early post
polypeptide
Prior art date
Application number
MX2018004366A
Other languages
English (en)
Inventor
Demaria Christine
R Cairns Victor
Vitko Jason
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2018004366A publication Critical patent/MX2018004366A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

En la presente memoria se proporcionan métodos para seleccionar una población de células que expresan un polipéptido blanco. En algunos aspectos, la descripción proporciona métodos para clasificar y seleccionar poblaciones de células hospedantes transfectadas con base a su expresión temprana de un polipéptido seleccionable. En determinadas modalidades, la clasificación se lleva a cabo usando clasificación celular activada por fluorescencia o clasificación celular activada magnéticamente basada en el polipéptido seleccionable. Dichos métodos de selección pueden utilizarse adicionalmente para generar poblaciones clonales de células productoras, p.ej., para fabricación a gran escala de un polipéptido blanco de interés.
MX2018004366A 2015-10-09 2016-10-07 Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos. MX2018004366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239515P 2015-10-09 2015-10-09
PCT/US2016/055918 WO2017062724A1 (en) 2015-10-09 2016-10-07 Early post-transfection isolation of cells (epic) for biologics production

Publications (1)

Publication Number Publication Date
MX2018004366A true MX2018004366A (es) 2018-08-01

Family

ID=57211576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004366A MX2018004366A (es) 2015-10-09 2016-10-07 Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.

Country Status (12)

Country Link
US (4) US11635363B2 (es)
EP (4) EP3359666B1 (es)
CN (3) CN108368505B (es)
AU (3) AU2016335699A1 (es)
CA (2) CA3001238C (es)
ES (2) ES3008383T3 (es)
HU (2) HUE069884T2 (es)
IL (4) IL258538B2 (es)
MX (1) MX2018004366A (es)
PL (2) PL3359665T3 (es)
SG (3) SG10202111233SA (es)
WO (2) WO2017062722A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
HUE069884T2 (hu) 2015-10-09 2025-04-28 Genzyme Corp Javított flare (áramlási citometriával csillapított reporter expresszió) technológia gyors tömeges válogatáshoz
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MX2018014154A (es) 2016-05-18 2019-05-06 Voyager Therapeutics Inc Polinucleotidos moduladores.
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING MORBUS HUNTINGTON
CL2016001661A1 (es) 2016-06-29 2017-03-03 Univ Chile Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
TWI795373B (zh) * 2016-10-07 2023-03-11 美商健臻公司 用於生物製劑生產之細胞早期轉染後分離（ｅｐｉｃ）
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119491003A (zh) 2017-05-05 2025-02-21 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法
JP7528066B2 (ja) 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
MX2023005938A (es) 2020-11-19 2023-05-29 Genzyme Corp Sistema de indicadores multiples de expresion atenuada de indicadores por citometria de flujo (flare) y sus metodos de uso.
WO2025186459A1 (en) 2024-03-08 2025-09-12 Sanofi Antigenic epstein barr virus polypeptides

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
EP0484411A4 (en) 1989-07-24 1992-06-17 Seragen, Inc. Prevention of internal initiation
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
WO1998037189A1 (en) 1997-02-25 1998-08-27 Qbi Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
ATE317011T1 (de) * 1999-07-12 2006-02-15 Genentech Inc Expressionsvektoren und anwendungsmethoden
US20020058243A1 (en) 2000-02-02 2002-05-16 Kurt Jarnigan Rapid, parallel identification of cell lines
WO2002070710A1 (en) 2001-03-01 2002-09-12 University Of California Method to identify ires elements
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
JP2005526517A (ja) 2002-05-22 2005-09-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 分泌性ポリペプチドの検出
US7119187B2 (en) 2002-07-09 2006-10-10 National Health Research Institutes Internal ribosome entry site of the labial gene for protein expression
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004009788A2 (en) * 2002-07-19 2004-01-29 Diversa Corporation Fluorescent proteins, nucleic acids encoding them and methods for making and using them
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
WO2004060910A2 (en) 2002-12-16 2004-07-22 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
EP3346010A1 (en) 2003-06-24 2018-07-11 Genzyme Corporation Novel beta-actin and rps21 promoters and uses thereof
US7776584B2 (en) 2003-08-01 2010-08-17 Genetix Limited Animal cell colony picking apparatus and method
JPWO2005094886A1 (ja) 2004-03-31 2008-02-14 キリンファーマ株式会社 Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
US7078179B2 (en) 2004-05-04 2006-07-18 Newlink Genetics Corporation Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
US20060188964A1 (en) * 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
ATE550432T1 (de) 2004-11-08 2012-04-15 Chromagenics Bv Selektion von wirtszellen mit proteinexpression auf hohem niveau
WO2006048459A2 (en) 2004-11-08 2006-05-11 Chromagenics B.V. Selection of host cells expressing protein at high levels
CN101068928A (zh) * 2004-12-14 2007-11-07 弗·哈夫曼-拉罗切有限公司 RNAi转染子的改良选择方法
WO2007118208A2 (en) 2006-04-10 2007-10-18 The Regents Of The University Of California Systems for collection of single cells and colonies
PL2064337T3 (pl) 2006-09-20 2012-12-31 Genzyme Corp Oparty na FACS i białku reporterowym układ do wysokowydajnego opracowywania białek terapeutycznych
EP2136817A4 (en) * 2007-03-05 2010-08-18 Newsouth Innovations Pty Ltd PROCESS FOR DETECTING AND MODULATING THE SENSITIVITY OF TUMOR CELLS AGAINST ANTI-MITOTIC AGENTS
JP6039552B2 (ja) * 2010-07-01 2016-12-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 高産生細胞株を選択するための改良された方法
JP2015516143A (ja) * 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
EP2700713B1 (en) * 2012-08-21 2016-07-13 Miltenyi Biotec GmbH Screening and enrichment system for protein expression in eukaryotic cells using a tricistronic expression cassette
US20160017319A1 (en) 2013-03-11 2016-01-21 Audrey Nommay Method of screening cell clones
CA2918117C (en) * 2013-07-31 2023-01-24 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
HUE069884T2 (hu) 2015-10-09 2025-04-28 Genzyme Corp Javított flare (áramlási citometriával csillapított reporter expresszió) technológia gyors tömeges válogatáshoz
TWI795373B (zh) 2016-10-07 2023-03-11 美商健臻公司 用於生物製劑生產之細胞早期轉染後分離（ｅｐｉｃ）

Also Published As

Publication number Publication date
EP4530350A2 (en) 2025-04-02
CA3001364A1 (en) 2017-04-13
IL258538B (en) 2022-12-01
CA3001238A1 (en) 2017-04-13
WO2017062722A2 (en) 2017-04-13
AU2022275507A1 (en) 2023-02-02
IL258538B2 (en) 2023-04-01
US20200018682A1 (en) 2020-01-16
IL297805A (en) 2022-12-01
EP3359665A2 (en) 2018-08-15
EP4567425A3 (en) 2025-10-08
US20170121734A1 (en) 2017-05-04
WO2017062722A3 (en) 2017-05-26
EP3359666A1 (en) 2018-08-15
EP4567425A2 (en) 2025-06-11
IL309289A (en) 2024-02-01
ES3008383T3 (en) 2025-03-24
HUE071193T2 (hu) 2025-08-28
US10317329B2 (en) 2019-06-11
IL258538A (en) 2018-05-31
CN108368504B (zh) 2022-07-19
US20230304913A1 (en) 2023-09-28
US11635363B2 (en) 2023-04-25
HK1259493A1 (en) 2019-11-29
IL258537A (en) 2018-05-31
SG11201802829YA (en) 2018-05-30
IL258537B2 (en) 2024-05-01
CN116660127A (zh) 2023-08-29
PL3359665T3 (pl) 2025-04-14
CN108368505A (zh) 2018-08-03
EP3359666B1 (en) 2025-02-19
US20170227441A1 (en) 2017-08-10
AU2022275507B2 (en) 2025-06-05
HUE069884T2 (hu) 2025-04-28
IL258537B1 (en) 2024-01-01
EP3359666C0 (en) 2025-02-19
CN108368504A (zh) 2018-08-03
SG11201802823VA (en) 2018-05-30
SG10202111233SA (en) 2021-11-29
ES3024209T3 (en) 2025-06-04
CN108368505B (zh) 2023-02-21
PL3359666T3 (pl) 2025-06-23
AU2016335699A1 (en) 2018-05-24
AU2025226783A1 (en) 2025-09-25
CA3001238C (en) 2024-06-25
EP4530350A3 (en) 2025-06-25
EP3359665C0 (en) 2024-11-13
WO2017062724A1 (en) 2017-04-13
EP3359665B1 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
MX2018004366A (es) Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
SG10201900323SA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
MY189778A (en) Method for producing retinal pigment epithelial cells
BR112018002214A2 (pt) ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho?
SG10201806890VA (en) Massively parallel single cell analysis
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
SA521421882B1 (ar) نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
NZ701791A (en) Cell culture compositions and methods for polypeptide production
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
MY178364A (en) Method for culturing microalgae of the genus aurantiochytrium in a culture medium without chloride and without sodium for the production of dha
MX2016014235A (es) Biosintesis microbiana de ergotioneina.
MX371025B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
EP4446338A3 (en) Cells and method of cell culture
AU2016250905A8 (en) Generation of muscle-lineage cells from stem cells
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
MY190347A (en) Production method for insoluble recombinant protein aggregate
MX2020003508A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2021001528A (es) Metodo para la produccion de celulas positivas para cd3.
MX2016000634A (es) Metodo optimizado para la ruptura de paredes celulares de chlorella por medio de homogeneizacion a muy alta presion.
WO2019217493A3 (en) Cell populations and gene expression associated with in vitro beta cell differentiation
MX369109B (es) Selección novedosa de vectores y métodos de selección de células hospederas eucarióticas.
EP4332231A3 (en) Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest